INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

PRNewsWire • May 21, 2026

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.

GlobeNewsWire • May 21, 2026

Is the Options Market Predicting a Spike in MiMedx Group Stock?

Investors need to pay close attention to MDXG stock based on the movements in the options market lately.

Zacks Investment Research • May 11, 2026

MiMedx: The Hard Math Behind My Downgrade To Hold

MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited.

Seeking Alpha • May 9, 2026

MIMEDX Announces Launch of G4Derm® Plus

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide.

GlobeNewsWire • May 8, 2026

MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 30, 2026

MIMEDX Announces First Quarter 2026 Operating & Financial Results

Reports  First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2026.

GlobeNewsWire • Apr 29, 2026

MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates

MiMedx (MDXG) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.06 per share a year ago.

Zacks Investment Research • Apr 29, 2026

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

GlobeNewsWire • Apr 22, 2026

Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline

MiMedx (MDXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 22, 2026